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L
atent autoimmune diabetes in adults
(LADA) is a term used to describe a
form of autoimmune diabetes that
resembles type 1 diabetes, but has a later
onset and slower progression toward an
absolute insulin requirement. Controver-
sies have been surrounding this concept
and several attempts have been made to
better characterize and classify it. But
LADA still remains poorly understood
and deﬁned (1). It was even debated
whether LADA exists as a distinct disease
entity or it just represents the end of a
wide spectrum of heterogeneous im-
mune-mediated diabetes (2,3). Uncer-
tainties concern almost all aspects of this
disease, including the nomenclature, di-
agnostic criteria, epidemiology, natural
history, and pathogenesis with genetic,
metabolical, and immunological aspects.
As a consequence, there is no clear man-
agementstrategyforit,intermsoftherapy
and prevention. An ideal therapeutic ap-
proach would aim not only at obtaining a
good metabolic control, but also at pro-
tecting residual -cell mass and function.
Even though 10% of adults with pre-
sumed type 2 diabetes at diagnosis in fact
have LADA, only a few studies so far have
evaluated therapeutic interventions for
LADA,usingahypoglycemicoranimmu-
nomodulatory agent.
DEFINITION AND
DIAGNOSTIC CRITERIA— Obvi-
ously, an important impediment in
establishing adequate and effective
management strategies is the lack of a
good understanding of the disease devel-
opment and of a clear deﬁnition. Difﬁcul-
ties reside from the fact that LADA has
features of an autoimmune disease
(mainly presence of autoantibodies at on-
set), with many genetic, immune, and
metabolic features of type 1 diabetes, but
alsosharessomeclinical,anthropometric,
and metabolic traits with type 2 diabetes
(Table 1) (2,4). As a matter of fact, LADA
was ﬁrst identiﬁed in a subset of pheno-
typic type 2 diabetes individuals who
were positive for islet cells antibodies
(ICAs), failed sulfonylurea therapy, and
needed insulin replacement earlier than
the ICA-negative patients, a ﬁnding sub-
sequently conﬁrmed by other groups
(5,6).
Various studies have used different
inclusion criteria and markers for disease
deﬁnition, and thus drawing conclusions
is difﬁcult (6,7). In the attempt to stan-
dardize the diagnosis of LADA, three cri-
teria are currently recommended, but all
ofthemhavesomepitfalls:criteria1and3
are not categorical traits and are highly
dependent on physicians’ decisions, and
criterion 2 is not speciﬁc for LADA (1).
Criterion 1: adult age at onset
Various cutoff ages have arbitrarily been
used (between 25 and 45 years), but the
proposed lower limit is now 30 years of
age (6,7). Nevertheless, since adulthood
startsearlierinlife,thislimitmightnotbe
all inclusive.
Criterion 2: presence of circulating
islet autoantibodies (at least one)
Because autoantibodies to insulin (IAA)
and tyrosine phosphatase-like insuli-
noma-associated protein 2 (IA2) have
been reported to be rather infrequent, the
diagnosis basically relies on identifying
glutamicaciddecarboxylaseautoantibod-
ies (GADAs), which is the best single
marker for screening. Epitope speciﬁcity,
antibody levels, and concomitant pres-
ence of ICAs discriminate two subcatego-
ries of LADA with a different risk toward
insulin dependency (8). Obviously, to as-
certain an accurate immune proﬁle of
LADA, further investigations should be
performed.
Criterion 3: lack of insulin
requirement for at least 6 months
after diagnosis
ThiscriterionisusedtodistinguishLADA
patients from those with type 1 diabetes,
but reports indicate that there is a high
bias in the time to insulin treatment initi-
ation and it does not depend on disease
process, but rather on physicians’ clinical
judgment(9).Inaddition,thenaturalhis-
tory of the disease, the timing of the
diagnosisinrelationtoit,aswellasclin-
ical features at diagnosis (e.g., presence
orabsenceofsymptoms)arefactorsthat
inﬂuence the period of insulin indepen-
dence (1).
Even though the question regarding
pathogenesis of LADA is still not fully an-
swered, it is clear now that there are
strong genetic and immunologic similar-
ities to type 1 diabetes, implying that
LADA is an autoimmune disease. The dif-
ferences between the two forms may be
due to genetic factors (e.g., presence of
protective HLA alleles in LADA) and/or
due to qualitative/quantitative dissimilar-
ities in the interaction with environment.
It is possible that in the disease course
there are differences in the antigenic rep-
ertoire triggering immune responses, fre-
quency of autoreactive immune cells,
and/or the degree of immune regula-
tion, but these aspects still need to be
investigated.
Regarding screening for LADA, no
deﬁnite recommendations can be done at
this time because of lack of enough evi-
dence coming from clinical trials (e.g., no
cost-beneﬁt assessment has been per-
formed). A possible algorithm for identi-
fying subjects with LADA is suggested
elsewhere (2).
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centstudieshaveprovedthatGADAtiters
have a bimodal distribution in LADA and
identify two subgroups of patients with
distinct clinical, autoimmune, and ge-
netic features: the one with high GADA
titerstendedtobeyoungerandleanerand
had a lower prevalence of metabolic syn-
drome and its components, with more
prominent traits of insulin deﬁciency
(lower C-peptide, higher A1C) and a pro-
ﬁle of more severe/extended autoimmu-
nity (higher prevalence of other diabetes
speciﬁc [IA-2, ICAs] or other autoim-
mune disease [thyroid peroxidase] auto-
antibodies) than individuals with lower
GADA titers (10). This ﬁnding is indica-
tive of the heterogeneity existing within
LADA: subjects with multiple and high
autoantibody titers resemble those with
type 1 diabetes in various features,
whereas individuals with single and low
autoantibodies titers resemble those with
type 2 diabetes (4,10). It might also have
therapeutic implications, since different
approaches may be applied to the two
groups.
THERAPEUTIC
INTERVENTIONS— Studies have
identiﬁed that 10% of adults with pre-
sumed type 2 diabetes at diagnosis have
markers of islet autoimmunity and be-
come insulin dependent sooner (6). This
category might therefore beneﬁt from
therapeutic interventions that are differ-
ent from those for type 2 diabetes and
somehow tailored to this condition.
While being safe and practical for ev-
eryday use, any potential therapeutic ap-
proach for LADA should not only aim at
obtaining good metabolic control, but
alsoallowbetterpreservationoftheresid-
ual -cell function, since it has been
proven that maintenance of even some
endogenous insulin production is associ-
ated with improved metabolic control
and better long-term disease outcome
(11). The key question is which drug (or
combination of drugs) is most effective in
obtaining these goals. Unfortunately,
there is no established therapeutic inter-
ventionforpatientswithLADAsofar,and
they are currently treated as patients with
type 2 diabetes.
Obviously, a critical issue is evalua-
tion of -cell mass and function in re-
sponse to treatment. A signiﬁcant
limitation of interventional trials in hu-
mans is that there are no “gold standard”
methods to directly measure -cell mass
in vivo. Newer imaging techniques like
positron emission tomography, magnetic
resonance imaging, scintigraphy, or neu-
rofunctional imaging approach are un-
dergoing development as noninvasive
methods of -cell mass measurement
(12). In the meantime, metabolic tests
have been routinely used as surrogate
markers, and studies have shown that
acute insulin response to arginine, glu-
cose and glucose-potentiated, and argin-
ine-induced insulin secretion can be used
as robust tests for estimation of -cell
mass (13). A well-validated and practical
means of quantifying insulin secretion in
vivo is measurement of C-peptide levels
under standardized conditions, which
has low variability and high reproducibil-
ity, making it a good and reliable marker.
In fact, the recommendation of an expert
panelconvenedbytheAmericanDiabetes
Association was that C-peptide response
(CPR) is the most appropriate measure of
function and clinical end point of inter-
vention in human clinical trials (14).
Although there is a good proportion
ofpatientswithLADA,surprisingly,there
are only a few studies that have evaluated
interventions for this group, and several
others are ongoing (15).
Hypoglycemic agents
Sulfonylureas. Sulfonylureas are com-
monly used for the treatment of type 2
diabetesandactbystimulatinginsulinre-
lease from the pancreatic -cells to lower
blood glucose levels. The insulin secre-
tion is triggered by binding of sulfonyl-
ureas to a speciﬁc site on the ATP-
sensitive K
 channels at the level of
plasma membrane, which leads to their
closure and subsequent opening of the
calcium channels and activation of an ef-
fector system of insulin release (16). De-
spite their initial efﬁcacy, there is a
progressive reduction in insulin-
producing capacity of pancreatic -cells
anddeteriorationofglycemiccontrolover
time. The cause might be exhaustion or
desensitization of -cells by prolonged
exposure to sulfonylureas and possibly
acceleration of oxidative stress and apo-
ptosis(17).Ithasalsobeensuggestedthat
stimulation of insulin release might be as-
sociated with increased autoantigen ex-
pression, which could be deleterious in
LADAbecauseitmightaccentuatetheon-
going autoimmune process (2,18). These
resultssuggestthattherapywithsulfonyl-
ureas in LADA would actually expedite
the progression toward -cells depletion
andthenecessityofinsulininitiation,and
several studies have conﬁrmed this hy-
pothesis (19–23).
One medium-term (12 months) ran-
domizedcontroltrial(RCT)comparedin-
sulin with sulfonylureas (glibenclamide)
plusinsulintreatment,byevaluatingmet-
abolic control (fasting blood glucose
[FBG]), insulin secretion (fasting C-
peptide [FCP]) and markers of autoim-
munity (ICA and GADA) at baseline and
at the end of study (20). After 1 year of
treatment, the group receiving insulin
alone had better metabolic control than
the sulfonylureas plus insulin group and
hadalsoimprovedthemarkersofautoim-
Table 1—Clinical and paraclinical features of LADA in comparison to type 1 and type 2 diabetes
Age at
onset
HLA
susceptibility
Autoimmunity
(autoantibodies) Ketosis BMI
Insulin
secretion
Metabolic
syndrome
Insulin
resistance Initial therapy
Type 1
diabetes Young/
adult
Yes (strong) Yes (strong) Present Normal Absent/low Infrequent Absent/
infrequent
Insulin
LADA Adult Yes Yes (by deﬁnition) Absent Normal/
high
Present (but
declines)
Variable Variable Insulin/OHA*
Type 2
diabetes Adult No No Absent High Present Frequent Present LSO/OHA
LSO, lifestyle optimization; OHA, oral hypoglycemic agents. *Preferable that sulfonylureas are not chosen as ﬁrst-line therapy.
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negative). No differences were found in
FCP between groups. Similarly, a study
examining the effect of adding insulin to
sulfonylureas (glibenclamide) and of
withdrawal of sulfonylureas on glycemic
control in type 2 diabetic patients seemed
to support the exclusion of sulfonylureas
in autoantibody-positive subjects, who
were less likely to respond to it (19).
A long-term (10 years) three-armed
RCT compared conventional treatment
(primarily with diet) to sulfonylureas and
to insulin (for patients with FBG between
6 and 14.9 mmol/l at baseline) and to sul-
fonylureas with insulin (for patients with
FBG15mmol/latbaseline)(21).Atotal
of 60% of the autoantibody-positive pa-
tients with FBG 15 mmol/l treated with
sulfonylureas progressed to insulin re-
quirementwithin2years(comparedwith
15% of the autoantibody-negative pa-
tients). Similarly, in individuals with FBG
of 6.0–14.9 mmol/l, the autoantibody-
positivegroupbecamemorerapidlyinsu-
lin requiring than the autoantibody-
negative group (and the highest proportion
wasfromtheautoantibody-positivegroup
allocated to sulfonylurea therapy). This
again suggests that the use of sulfonyl-
ureas may accelerate insulin require-
ment when compared with conventional
intervention.
Two RCTs conducted in Japan com-
pared sulfonylureas (glibenclamide) with
insulin treatment in LADA patients. The
ﬁrststudyincludedICA
subjectsandre-
ported that two of ﬁve patients treated
with sulfonylureas required insulin treat-
ment within 24 months due to failure of
treatmentwithsecondaryoralhypoglyce-
mic agents (22). At the end of study (30
months), the sulfonylureas group had a
worsening of metabolic control and
showed a progressive deterioration of
-cell function (during the study period
serum stimulated CPR [after an oral glu-
cosetolerancetest]decreasedwithalmost
40% from baseline). The second study
(the Tokyo study, which included
GADA
 subjects) had used as primary
outcome an integrated value of serum
CRP to a 75-g oral glucose tolerance test
(CPRsumofCPRat0,30,60,90,and
120 min) and deﬁned insulin-dependent
stageasCPR4.0ng/ml(23).Similarto
the previous trial, this study reported that
the group receiving sulfonylurea therapy
progressedin greaterproportiontothein-
sulin-dependent stage during 57 months
of follow-up. The same trends were seen
in subgroups of patients that had a pre-
served CPR and had high GADA titers at
baseline. The high GADA titers subgroup
treated with sulfonylureas had the great-
est proportion of patients progressing to
insulindependency.Moreover,CPRde-
creased signiﬁcantly in the sulfonylureas
group over 5 years, whereas the same pa-
rameter remained unchanged in the insu-
lin group.
Even though it is difﬁcult to general-
ize these data because the studies had dif-
ferent selection criteria and ethnicity as
well as different outcome parameters and
follow-up durations, taken together, they
do suggest that sulfonylureas accelerate
(or at least do not protect against) pro-
gressive -cell failure and are similar to
(or worse than) insulin in obtaining good
metabolic control. Therefore, sulfonyl-
ureasshouldnotbeusedasﬁrst-linether-
apy in patients with LADA.
Insulin. It would probably seem some-
how paradoxical to initiate early insulin
treatment in LADA, since this disease is
deﬁned by lack of insulin requirement at
onsetandthetherapeuticaimisalteration
of the risk of progression toward insulin
dependency. The rationale for early insu-
lininterventionthoughwouldbeimprov-
ing glycemic control while protecting
-cell function. The exact mechanisms
for the apparent beneﬁcial effects of insu-
lin treatment reported in several studies
are not yet fully understood, but it is
thought that administration of exogenous
insulin would allow -cell rest, at least in
part by downregulating the -cell metab-
olism and/or by releasing them from the
hyperglycemic stress (24). The conse-
quence is a decrease in the severity of in-
sulitis and in the number of inﬁltrative
antigen-presenting cells in and around
the pancreatic islets (25). A number of
experiments suggested that active -cells,
producing high amounts of insulin, are
more susceptible to immune-mediated
killingandarealsoassociatedwithhigher
antigen expression (18,26). Thus, a re-
duction of -cell function and of inﬂam-
matory processes in the islets would lead
to decreased antigen expression on
-cells and subsequent reduction of T-
cell responses (27). Other possible expla-
nations would be that exposure to
exogenous insulin would actually pro-
mote Th2 immunity in humans, as indi-
cated by an increase in IgG1 and IgG4-IA
(antibodies to insulin) (although no sec-
ondary spreading to other autoantigens)
and induce an activation of insulin-
speciﬁc regulatory T-cells (Tregs)
(28,29). Finally, as insulin is a major au-
toantigen in diabetes (mainly in type 1A),
it is thought that immunization with ex-
ogenous insulin would determine im-
mune modulation possibly by tolerance
induction or “bystander” suppression of
autoreactive T-cells through the local re-
lease of regulatory cytokines (27). Never-
theless, it should be noted that parenteral
insulin failed to prevent the onset of dia-
betes in high-risk relatives of patients
with type 1 diabetes in the Diabetes Pre-
vention Trial-1, and only oral insulin de-
layed diabetes onset in a subgroup of
individuals with high titers of autoanti-
bodies to insulin. This could imply that
the timing and speciﬁcity of intervention,
selection of adequate candidates, or other
(poorer deﬁned) aspects of the immune
response are critical for the success of in-
tervention (30).
Someoftheabove-mentionedstudies
conducted in LADA patients have shown
that insulin treatment is associated with
betteroutcomeintermsofmetaboliccon-
trol, insulin secretion, and autoimmune
responses against pancreatic -cells. In
two studies, patients receiving insulin
monotherapy had improved markers of
autoimmunity(sixofeightpatientsinone
and four of ﬁve patients in the other be-
came ICA negative) (20,22). Glycemic
control was signiﬁcantly improved with
insulin monotherapy (after exclusion of
sulfonylureas) in the 12-month Cuban
study, as evaluated by FBG (20). In the
ﬁrst Japanese trial, the 2-h blood glucose
level during the 100-g oral glucose toler-
ance test tended to decrease from the
baseline values, but the A1C remained
unchanged 30 months later (22). Impor-
tantly, the insulin-treated group had an
increased stimulated CPR at 30 months
(with60%frombaseline)(22).Thesec-
ond Japanese study showed maintenance
of the serum CPR over 5 years (23).
Moreover, subgroup analysis suggested
that patients with high GADA titers and
preserved CPR at baseline were less likely
toprogresstotheinsulin-dependentstage
with early administration of small doses
of insulin.
Overall, these results are encouraging
because they imply that the insulin-
treated patients maintain better -cell
function. The optimal insulin regimen is
not clear. Given that the loss of rapid in-
sulin release occurs early in LADA, re-
placement with fast-acting insulin might
be beneﬁcial. However, from a practical
point of view, it might be difﬁcult to ini-
tiate multiple insulin injection therapy in
LADA patients, especially if their blood
-Cell protection and therapy for LADA
S248 DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 care.diabetesjournals.orgglucose levels are moderately increased.
Thus, a long-acting insulin injection
might be a good alternative.
Insulin sensitizers (metformin, thiazo-
lidinediones). Because (at least some)
patients with LADA have features of met-
abolic syndrome and a certain degree of
insulin resistance, they might beneﬁt
from therapy with an insulin-sensitizing
drug that improves the peripheral action
of insulin and thus indirectly protects
-cells from continuous hyperstimula-
tion of its release.
The speciﬁc role of metformin in
LADA is not known, since there are no
studies evaluating it in this speciﬁc group
of patients. In addition, a potential risk
associated with its use is occurrence of
lacticacidosisinpatientsthatprogressto-
ward insulin dependency (2).
The thiazolidinediones (TZDs) are in
turn a more appealing therapeutic ap-
proach because, apart from their effect on
glucose homeostasis and lipid metabo-
lism (through peroxisome proliferator–
activated receptor-), there is evidence
that they have other potential beneﬁcial
effects on islet -cells (17). It has been
shownthatTZDsimproveinsulincontent
and secretion, preserve -cell mass and
islet structure, have anti-inﬂammatory ef-
fects, protect -cells from oxidative stress
and apoptosis, and even facilitate -cell
proliferation (31,32). Data from animal
models suggest that TZD administration
has favorable effects on preservation and
augmentation of -cell mass through a
combination of enhanced proliferation
and decreased apoptosis (32,33). This ef-
fect might be due to regulation of genes
controllingproliferation,growth,anddif-
ferentiation and involve the key -cell
regulatory transcription factor pancre-
atic and duodenal homeobox 1 (Pdx1)
(33,34). This might be signiﬁcant for
the clinical management of LADA in
therapeutic efforts aimed at -cell
protection.
A recent RCT compared rosiglitazone
plus insulin with insulin alone in LADA
patients over a total follow-up period of
18 months (35). Results of 17 patients at
12 months showed no signiﬁcant change
in A1C in the insulin group and a signif-
icantdecreasefrombaselineintherosigli-
tazone plus insulin group, but at 18
months, this improvement in glycemic
control was no longer seen. -Cell func-
tion was evaluated by measurement of
FCP, by CPR after a 75-g load, and by the
difference between the two (	CP 
CPR 
 FCP). At 18 months, the insulin
alone group had a signiﬁcant decrease of
the FCP, CPR, and 	CP compared with
baseline, while all of the parameters were
maintained in the rosiglitazone plus insu-
lin group. Even though rosiglitazone plus
insulindidnotimprovemetaboliccontrol
signiﬁcantly more than insulin alone, it
appeared to have a beneﬁcial effect in
termsofmaintainingC-peptidelevels(es-
pecially stimulated C-peptide) in the long
term. The impact of rosiglitazone alone
was not assessed in this pilot study, but
theresultssuggestthatitwouldbeworthy
to further evaluate the beneﬁt of using
TZDs in patients with LADA.
Incretins. Incretin mimetics are a new
class of pharmacologic agents developed
to improve metabolic control in patients
with type 2 diabetes. The most advanced
drug of this class is exendin-4, which acts
as a full agonist at the glucagon-like pep-
tide (GLP)-1 receptor and has glucoregu-
latory actions similar to the incretin
hormones (glucose-dependent enhance-
mentofinsulinsecretionandinhibitionof
glucagon secretion), as well as slows gas-
tric emptying and reduces food intake
(36). In addition, exendin-4 has been
shown in vitro and in animal models to
havetrophiceffectsonthepancreas,since
it modiﬁes the susceptibility to apoptotic
injury and stimulates -cell proliferation
and islet neogenesis from precursor cells
(37). Like the TZDs, exendin-4 has islet
growth-promoting effects through regu-
lation of genes controlling proliferation,
growth, and differentiation, apparently
by targeting different components of the
epigenetic machinery (34). It induces
multiple signaling pathways intrinsic to
-cells (including expression of Pdx-1),
which results in expansion of -cell mass
through promoting differentiation of pre-
cursor into mature -cells and stimula-
tion of mature -cell proliferation
(38,39). Therefore, the reports of ex-
enatide increasing the mass of -cells, in
addition to its glucose-lowering effects,
provide encouragement for its use in the
treatment of LADA.
There are a few studies evaluating
GLP-1 (and exendin-4) in subjects with
type 1 diabetes, and they showed reduc-
tion of fasting hyperglycemia and glyce-
mic excursions after a meal, accompanied
by inhibition of abnormal rises of blood
levels of glucagon (40). Additionally, in
islet transplant recipients, exendin-4 has
stimulated insulin secretion and demon-
strated an ability to reduce exogenous in-
sulin requirements. Current clinical trials
test the hypothesis that its use at the time
ofislettransplantationmightbeofhelpin
preserving islet mass (41). Although not
evaluated yet in LADA, these agents have
a potential therapeutic value in such a
setting.
Immune modulation
Since LADA is an autoimmune disease
caused by failure to maintain tolerance
to autoantigens, targeting them through
administration of autoantigen in a
tolerogenic regimen should provide an
effective means of controlling the auto-
immune process by inducing tolerance
throughdeviationoftheTh1phenotype
of the antigen-reactive cells toward a
Th2 phenotype.
Thebeneﬁcialeffectofanimmunein-
tervention in LADA in protecting residual
-cell function may be hampered by sev-
eral factors such as age at diagnosis, met-
abolic control, and extension of -cell
destruction. The latter is inﬂuenced by
HLA genotypes (42). Whether different
HLA genotypes associated with LADA
may affect the outcome in terms of -cell
function is still unknown, but recent data
seemtoindicatethatpatientspossessinga
moderate-orlow-riskHLAgenotype,asis
the case in LADA, have a higher residual
-cell function (42). We may speculate
that LADA patients with such genotypes
mightbeneﬁtmoreintermsof-cellpro-
tection after immune intervention.
The antigens that have been used so
far as tolerogens in LADA have included
the following: insulin, GAD, heat shock
protein (HSP), and their constituent
peptides.
Peptide of HSP60 (DiaPep277). HSP60
is a ubiquitous protein, part of a highly
conserved family of intracellular chaper-
ones, also located in the mitochondria
and mature insulin–secretory granules of
pancreatic -cells, with an important reg-
ulatory role in the innate immune system
(43) and considered an important au-
toantigen in diabetes. The dominant
epitopeofHSP60wasfoundtobepeptide
HSP277, and its modiﬁed form, Dia-
Pep277 (generated to increase its stability
in vivo), has been used in patients
with recent-onset type 1 diabetes for pre-
vention of further -cell loss (44,45).
DiaPep277 has shown suggestive evi-
denceofbetterpreservationofC-peptide,
since at the end of the follow-up period,
the intervention group had improved
mean C-peptide levels and required sig-
niﬁcantlylessexogenousinsulintoobtain
similar A1C as the placebo group. Inter-
estingly, the drug treated group had a
Cernea, Buzzetti, and Pozzilli
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a proinﬂammatory Th1 to a predominant
Th2 phenotype (with interleukin [IL]-10
and IL-13) (44).
A phase II double-blind multicenter
RCT has been conducted in 60 patients
with LADA, 30–50 years old, and within
2 to 60 months after diagnosis for evalu-
ation of safety, tolerability, and clinical,
metabolic, and immunological efﬁcacy
of multiple subcutaneous doses of
DiaPep277 (46). Results have not yet
been published, but a brief report sug-
gests good safety and tolerability and
possibleresponsetoDiaPep277inthese
patients (46).
GAD65 (Diamyd). The 65-kDa isoform
of GAD (GAD65) is found in -cells (and
other tissues) and considered a major au-
toantigeninautoimmunediabetes(47).A
large body of evidence has indicated that
antibodies to GAD65 may be found in
70–75% of type 1 diabetic patients and
that GADA is the most sensitive autoanti-
body marker for LADA (8).
An alum-formulated recombinant
human form of GAD65 (Diamyd) has
been evaluated in 47 patients with LADA
inadose-escalationdouble-blindphaseII
RCT (48). After 24 weeks, the 20 g dose
group showed an increase from baseline
in the mean log FCP and stimulated log
C-peptide. These changes were accompa-
niedbyanincreaseofthepurportedTregs
subsets (CD4
CD25
/CD4
CD25

 cell
ratio) in the peripheral blood. With re-
gards to glycemic control, an increase in
the FBG and A1C was seen in no-effect
dose groups (placebo and 4 g), but in
comparison, a decrease of these parame-
ters was noted in the groups receiving
higher doses (20, 100, and 500 g). No
study-related adverse effects were re-
ported. A more recent study in pediatric
type 1 diabetic subjects indicated that
GAD-alum treatment had no signiﬁcant
effect on FCP after 15 months, but after
30 months, FCP and stimulated C-
peptideshowedasigniﬁcantlysmallerde-
cline compared with placebo (although
this apparent protective effect was seen
only in subjects treated 6 months after
diagnosis and was not accompanied by
change in insulin requirement) (49). Fur-
ther studies are required in the setting of
LADA.
Anti-CD3monoclonalantibodies(anti-
CD3). Because the initial antigenic rep-
ertoire as the primary target of the
immuneattackinautoimmunediabetesis
still not well deﬁned, considerable efforts
have been devoted to nonantigenic im-
mune interventions. Although the exact
mechanismsresponsiblefortheactionsof
the anti-CD3 are still not fully elucidated,
thereareseveralpossibilities:inductionof
antigenic modulation, anergy, and/or ap-
optosis in activated cells and immune tol-
erance through adaptive Tregs (50).
Noteworthy outcomes have been seen in
two studies in new-onset type 1 diabetes
using two different humanized anti-CD3,
and both have reported preservation of
-cell function with maintenance of
higher endogenous insulin secretion as-
sessed by CPR and concomitant reduc-
tioninA1Clevelsandinsulinusageinthe
treated group over at least 1 year (51,52).
This could be a possible beneﬁcial inter-
vention also for LADA patients, but stud-
ies are required to conﬁrm the feasibility
of anti-CD3 therapy for this group.
CONCLUSIONS— A number of at-
tractive therapeutic interventions may be
envisioned for prevention of -cell dete-
rioration and progression toward insulin
dependency, which include hypoglyce-
mic and immunomodulatory agents, and
possiblyacombinationofthose,provided
they are safe. Because the autoimmune
process in LADA is thought to be slower
thaninchildhoodtype1diabetes,thereis
a larger window of opportunities for in-
tervention. An appropriate therapeutic
approach would be one that offers a good
metabolic control and at the same time
improvesthenaturalhistoryofthedisease
(i.e., maintains/increases the residual
-cell mass and/or function).
There are no current guidelines for
treatment of LADA, since this condition
stillhasnocleardeﬁnition.Whilewaiting
for the results of current and future stud-
ies, a couple of points should be taken
into consideration emerging from the few
studies that have evaluated interventions
for LADA (reviewed here), even though
their results are difﬁcult to generalize.
Sulfonylureas seemed to provide either
similar or poorer glycemic control than
insulin alone and caused earlier insulin
dependence.Therefore,untilprovencon-
trary, sulfonylureas should not be used as
ﬁrst-line therapy. Small doses of insulin
given early after diagnosis might be ben-
eﬁcial in maintaining stimulated C-
peptide values and thus, supposedly,
-cellfunction.Hypoglycemicagentslike
TZDorexenatide,whichalsohavepoten-
tial beneﬁcial effects on preservation/
augmentation of -cell mass, might be a
good therapeutic option, but this has to
be conﬁrmed by clinical trials. Consider-
ing the autoimmune pathogenesis, thera-
pies using immunomodulatory agents
might be of beneﬁt, but clinical studies
should clearly demonstrate their beneﬁt
in LADA before future treatment plans
could incorporate them in the effort to
arrest the progression of disease.
Obviously, high-quality studies are
furtherneededtoevaluatevariousaspects
ofthisformofautoimmunediseaseandto
deﬁne the best strategy for treating it.
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